Polaryx Therapeutics, Inc. Common Stock Total Liabilities
Polaryx Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Polaryx Therapeutics, Inc. Common Stock (PLYX) has total liabilities worth $873.00K USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Polaryx Therapeutics, Inc. Common Stock working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of Polaryx Therapeutics, Inc. Common Stock (2023–2025)
Total liabilities of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025. This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Polaryx Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Polaryx Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quantum Graphite Ltd
AU:QGL
|
Australia | AU$10.23 Million |
|
Hansol Holdings Co Ltd
KO:004150
|
Korea | ₩243.81 Billion |
|
Axcen Photonics
TWO:6530
|
Taiwan | NT$88.84 Million |
|
Empress Royalty Corp
V:EMPR
|
Canada | CA$7.23 Million |
|
Hasen-Immobilien AG
STU:ABHA
|
Germany | €83.22 Million |
|
Banco Santander Río S.A
BA:BRIO
|
Argentina | AR$19.89 Trillion |
|
AIAI Holdings Corporation Class A Common Stock
NASDAQ:AIAI
|
USA | $317.93 Million |
|
NIP Group Inc. American Depositary Shares
NASDAQ:NIPG
|
USA | $73.10 Million |
Liability Composition Analysis (2023–2025)
This chart breaks down Polaryx Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Polaryx Therapeutics, Inc. Common Stock.
Liquidity & Leverage Metrics
Polaryx Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Polaryx Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Polaryx Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Polaryx Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual total liabilities of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $855.00K | +195.85% |
| 2024-12-31 | $289.00K | -72.16% |
| 2023-12-31 | $1.04 Million | -- |
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-… Read more